“Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives”.Mechanisms of Ageing and Development199: 111572.(October 2021).doi:10.1016/j.mad.2021.111572.PMID34536446.
“Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization”.Journal of Medicinal Chemistry47(14): 3491–3494.(July 2004).doi:10.1021/jm049766q.PMID15214776.
“Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity”.The Journal of Biological Chemistry276(38): 35305–35311.(September 2001).doi:10.1074/jbc.M104028200.PMID11418606.
“[Type 1 plasminogen activator inhibitor: its role in biological reactions]”.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology32(5): 487–489.(May 1991).PMID1870265.
“Plasminogen activator inhibitor 1: physiological and pathophysiological roles”.News in Physiological Sciences17(2): 56–61.(April 2002).doi:10.1152/nips.01369.2001.PMID11909993.
“Plasminogen activator inhibitor-1 and the kidney”.American Journal of Physiology. Renal Physiology283(2): F209–F220.(August 2002).doi:10.1152/ajprenal.00032.2002.PMID12110504.
“Association between platelet activation and fibrinolysis in acute stroke patients”.Neuroscience Letters384(3): 305–309.(August 2005).doi:10.1016/j.neulet.2005.04.090.PMID15916851.
“Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn”.Biological Chemistry383(7–8): 1143–1149.(2003).doi:10.1515/BC.2002.125.PMID12437099.
“The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors”.Thrombosis and Haemostasis91(3): 425–437.(March 2004).doi:10.1160/TH03-12-0764.PMID14983217.
“Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis”.Thrombosis and Haemostasis91(3): 438–449.(March 2004).doi:10.1160/TH03-12-0784.PMID14983218.
“Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer”.Thrombosis and Haemostasis91(3): 450–456.(March 2004).doi:10.1160/TH03-12-0798.PMID14983219.
“Plasminogen activator inhibitor type 1: the two faces of the same coin”.Current Opinion in Nephrology and Hypertension13(1): 39–44.(January 2004).doi:10.1097/00041552-200401000-00006.PMID15090858.
“Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk”.Thrombosis and Haemostasis91(5): 861–872.(May 2004).doi:10.1160/TH03-08-0546.PMID15116245.
“Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease”.Current Opinion in Pharmacology5(2): 149–154.(April 2005).doi:10.1016/j.coph.2005.01.007.PMID15780823.
“Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease”.Thrombosis and Haemostasis93(4): 631–640.(April 2005).doi:10.1160/TH05-01-0033.PMID15841306.
“[Role of PAI-1 in gynaecological malignancies]”.Zentralblatt für Gynakologie127(3): 125–131.(June 2005).doi:10.1055/s-2005-836407.PMID15915389.
“Plasminogen activator inhibitor type 1 gene polymorphism and sepsis”.Clinical Infectious Diseases41(Suppl 7): S453–S458.(November 2005).doi:10.1086/431996.PMID16237647.
“Plasminogen activator inhibitor-1, adipose tissue and insulin resistance”.Current Opinion in Lipidology18(3): 240–245.(June 2007).doi:10.1097/MOL.0b013e32814e6d29.PMID17495595.